Characterization of Immunosuppressive Signing of Cervical Cancer

NCT02875990 | Unknown

• 2 other identifiers: 2014-032015-A00699-40
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer. The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.

Conditions

Cervical Cancer

Outcome Measures

Primary Outcomes (1)

• Lack of tumor emboli histological analysis

  Patients with good prognosis of cervical cancer

  60 months

Study Arms (1)

patients with invasive cervical cancer

EXPERIMENTAL

Blood sample

Biological: Blood sample

Interventions

Blood sample BIOLOGICAL

patients with invasive cervical cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The women presenting for initial therapeutic management of cervical cancer
• Elderly patients over 18 years
• Patients beneficiary of a social security scheme
• Pregnant women can not participate in this study
• Women known to be HIV positive will not participate in this study

You may not qualify if:

• Patients with a recurrence of a treaty cervical cancer
• Patients with a history of pelvic radiotherapy
• Patients unable to receive informed about the progress and objectives of the study
• Patients not receiving a social security scheme
• Patients who have not signed informed consent
• Immunocompromised patients and pregnant women

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Assistance Publique Hôpitaux de Marseille

Marseille, 13354, France

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Xavier CARCOPINO, PU-PH

CONTACT

xavier.carcopino@ap-hm.fr

Urielle DESALBRES, Director

CONTACT

04.91.38.27.47; drci@ap-hm.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2016
• First Posted: August 23, 2016
• Study Start: September 1, 2016
• Primary Completion: September 1, 2024
• Study Completion: September 1, 2024
• Last Updated: August 23, 2016

Record last verified: 2016-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)